Why Promising Antibody Candidates Fail Before Clinical Trials – and How to Avoid It

Despite the growing antibody therapeutics market, with revenues projected to reach USD 450 billion by 2033 ¹, the journey from discovery to approval remains fraught with attrition. Only a small fraction of candidates make it beyond early development stages ². 

Failures at this point not only waste resources but also delay much-needed treatments reaching patients. Understanding why antibody candidates fail early and how to prevent it is therefore critical to pipeline productivity.

This article explores the most common reasons for early-stage failure and strategies to de-risk therapeutic antibody development from the outset.

Common Reasons Why Antibody Candidates Fail in Early Development

There are various reasons why antibody candidates fail in early development. We listed the most common reasons: 

Poor Developability Profiles

Many candidates show promise in initial screening yet fail due to poor biophysical properties that limit their manufacturability and scalability. Key issues include low solubility, aggregation propensity, and poor expression yields ³. For instance, it has been found that over 30% of clinical-stage antibodies had suboptimal biophysical profiles, which can compromise stability, formulation, and process development ⁴.

Aggregation, in particular, increases immunogenicity risk and complicates purification. Early developability assessments can flag liabilities such as hydrophobic patches or unstable frameworks ⁵. Ignoring these factors often leads to late-stage reformulation, costly engineering efforts, or program termination.

Unfavorable Pharmacokinetics or Stability

Pharmacokinetics (PK) and molecular stability are key determinants of therapeutic viability. Rapid clearance or poor half-life limits exposure and efficacy, especially for chronic indications. For example, it has been stated that certain bispecific antibodies exhibited aberrant PK due to unanticipated liver clearance mechanisms in cynomolgus monkeys ⁶.

Chemical instability is another common culprit. Deamidation, oxidation, and isomerization can reduce antigen binding and increase degradation during production or storage ⁷. These modifications, if unaddressed, compromise both potency and safety profiles, resulting in early project discontinuation.

Immunogenicity Concerns

Immunogenicity remains a persistent hurdle. Even fully human or humanized antibodies can elicit anti-drug antibody (ADA) responses, compromising efficacy and causing adverse events. Sequence liabilities such as non-human motifs, unstructured regions, or specific PTMs can trigger T cell–dependent immune reactions ⁸.

Often, under fast development timelines, comprehensive immunogenicity assessments are delayed, only to surface as safety issues in preclinical or early clinical phases. Mitigation strategies, including sequence engineering and epitope mapping, must be incorporated early to reduce this risk.

Strategies to Reduce Early Development Failures

To improve the success rate of antibody candidates, developers should implement the following approaches:

1. Robust Developability Assessments

Integrate computational and experimental developability profiling during candidate selection to assess solubility, aggregation, and expression risk. Early elimination of problematic molecules avoids costly failures downstream.

2. Engineering for Stability and Manufacturability

Targeted engineering can reduce deamidation-prone residues, enhance FcRn binding for half-life extension, or optimize frameworks for higher expression yields ⁹. Even minor sequence modifications can substantially improve developability without compromising activity.

3. Parallel Functional and Safety Screening

Conduct simultaneous potency, specificity, and immunogenicity assays to fully characterize candidate risks. This integrated approach de-risks candidates early and informs design decisions for later stages ¹⁰.

4. Partnering with Experienced CDMOs

Collaborating with an experienced recombinant antibody production service accelerates high-quality material generation while ensuring robust, scalable processes. Expertise in expression platforms, purification strategies, and Fc engineering reduces the risk of surprises in preclinical or clinical production ¹⁰.

How evitria Helps De-risk Early Antibody Development

At evitria, we understand that early-stage failures can derail entire development programs, wasting valuable time, resources, and opportunities. That’s why our services are designed not just to produce antibodies, but to empower you with the confidence needed to make informed, data-driven decisions at every stage.

We provide:

High reproducibility across diverse antibody formats: With more than 13 years of experience and over 120,000 production runs completed, our proprietary CHO-based transient expression systems deliver consistent, scalable yields. This reproducibility is critical for reliable candidate evaluation and ensuring that promising antibodies maintain their properties from discovery through to preclinical studies and beyond.

Rapid production and comparison of multiple variants: Speed without quality is meaningless. We combine both, enabling rapid production of multiple antibody candidates for side-by-side comparison. This accelerates your developability, potency, and manufacturability assessments, facilitating confident go/no-go decisions and efficient progression of the best candidates.

Fc engineering and pairing technology support: Our expertise extends beyond expression. We support targeted Fc engineering, including glycoengineering for afucosylation to enhance ADCC, and stability modifications to optimize half-life. For bispecific antibodies, our licensed bYlok® pairing technology ensures >95% correct heavy and light chain assembly, reducing mispairing and simplifying purification – ultimately de-risking your path to IND-enabling studies.

Expert guidance tailored to your project goals: Our team of scientists and project managers works closely with you to understand your therapeutic objectives, recommend optimal expression and engineering strategies, and troubleshoot challenges before they become bottlenecks. This collaborative approach ensures that your molecules are not only expressed efficiently, but are ready for scale-up and clinical translation.

At evitria, we provide the infrastructure, expertise, and strategic partnership to advance your therapeutic pipeline with confidence and clarity. Let’s talk about your specific antibody project. 

References

1. Future Market Insights. “Antibodies Market Outlook (2023 to 2033).” Future Market Insights, https://www.futuremarketinsights.com/reports/antibodies-market. Accessed 19 June 2025. ↩︎
2. Kaplon, Hélène et al. “Antibodies to watch in 2022.” mAbs vol. 14,1 (2022): 2014296. doi:10.1080/19420862.2021.2014296 ↩︎
3. Raybould, Matthew I J et al. “Five computational developability guidelines for therapeutic antibody profiling.” Proceedings of the National Academy of Sciences of the United States of America vol. 116,10 (2019): 4025-4030. doi:10.1073/pnas.1810576116 ↩︎
4. Jain, Tushar et al. “Biophysical properties of the clinical-stage antibody landscape.” Proceedings of the National Academy of Sciences of the United States of America vol. 114,5 (2017): 944-949. doi:10.1073/pnas.1616408114 ↩︎
5. Bailly, Marc et al. “Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.” mAbs vol. 12,1 (2020): 1743053. doi:10.1080/19420862.2020.1743053 ↩︎
6. Datta-Mannan, Amita et al. “Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.” mAbs vol. 8,5 (2016): 969-82. doi:10.1080/19420862.2016.1178435 ↩︎
7. Adrian Valentin Dinh-Fricke, Oliver Hantschel. ”Improving the pharmacokinetics, biodistribution and plasma stability of monobodies”. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1393112 ↩︎
8. Jawa, Vibha et al. “T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.” Frontiers in immunology vol. 11 1301. 30 Jun. 2020, doi:10.3389/fimmu.2020.01301 ↩︎
9. Madsen, Andreas V et al. “Design and engineering of bispecific antibodies: insights and practical considerations.” Frontiers in bioengineering and biotechnology vol. 12 1352014. 25 Jan. 2024, doi:10.3389/fbioe.2024.1352014 ↩︎
10. Kozlowski, Steven, and Patrick Swann. “Current and future issues in the manufacturing and development of monoclonal antibodies.” Advanced drug delivery reviews 58.5-6 (2006): 707-722. ↩︎